Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study

Biomedical Chromatography

Volumn 26, Issue 11, 2012, Pages 1436-1443

  Ravi, Vasu Babu ^a,b   Mullangi, Ramesh ^c   Inamadugu, Jaswanth Kumar ^b   Pilli, Nageswara Rao ^b   Gajula, Ramakrishna ^b   Ponneri, Venkateswarlu ^d  

^a RAYALASEEMA UNIVERSITY   (India)

^b Wellquest Clinical Research Laboratories   (India)

^c Industrial Suburb   (India)

^d SRI VENKATESWARA UNIVERSITY   (India)

Author keywords

Atorvastatin; Human plasma; LC MS MS; Method validation; Niacin; Pharmacokinetics

Indexed keywords

LIQUID CHROMATOGRAPHY; PHARMACOKINETICS; PLASMA (HUMAN); PYRIDINE; SOLVENT EXTRACTION;

ATORVASTATIN; HUMAN PLASMAS; INTERNAL STANDARDS; ITS APPLICATIONS; LC-MS-MS; LC.MS/MS; METHOD VALIDATIONS; NIACIN; PHARMACOKINETIC STUDIES; SIMULTANEOUS DETERMINATIONS;

ELECTROSPRAY IONIZATION;

ATORVASTATIN; NEVIRAPINE; NICOTINIC ACID;

ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; ELECTROSPRAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; PLASMA CONCENTRATION-TIME CURVE;

EID: 84867140050     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2715     Document Type: Article

References (26)

1. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon RJ, Isaacsohn SL, Weiss SR, Keilson LM, Brown MV, Miller VT and Shurzinske LJ. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Journal of the American Medical Association 1996; 275: 128-133.
2. Borek-Dohalsky V, Huclova J, Barrett B, Nemec B, Ulc I and Jelinek I. Validated HPLC- MS-MS method for simultaneous determination of atorvastatin and 2-hydroxy atorvastatin in human plasma-pharmacokinetic study. Analytical and Bioanalytical Chemistry 2006; 386: 275-285.
3. Bullen WW, Miller RA and Hayes RN. Development and validation of a high- performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho- hydroxy atorvastatin and para-hydroxy atorvastatin in human, dog and rat plasma. American Society for Mass Spectrometry 1999; 10: 55-66.
4. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL Belder R, Joyal SV, Hill KA, Pfeffer MA and Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine 2004; 350: 1495-1504.
5. Chi J, Jayewardene AL, Stone JA and Aweeka FT. An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2003; 31: 953-959.
6. Ghosh C, Jain I, Gaur S, Patel N, Upadhyay A and Chakraborty BS. Simultaneous estimation of atorvastatin and its two metabolites from human plasma by ESI-LC-MS/MS. Drug Testing and Analysis 2011; 3: 352-362.
7. Guyton JR. Combination drug therapy for combined hyperlipidemia. Current Cardiology Reports 1999; 1: 244-250.
8. Inamadugu JK, Damaramadugu R, Mullangi R and Ponneri V. Simultaneous determination of niacin and its metabolites - nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Biomedical Chromatography 2010; 24: 1059-1074.
9. Jain KS, Kathiravan MK, Somani RS and Shishoo CJ. The biology and chemistry of hyperlipedemia. Bioorganic and Medicinal Chemistry 2007; 15: 4674-4699.
10. Jani AJ, Dasandi B, Rathnam S and Mehta AA. Liquid chromatographic-MS/MS determination of atorvastatin and metabolites in human plasma. Eurasian Journal of Analytical Chemistry 2010; 5: 46-52.
11. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, Gotto AM, Greten H, Kastelein JJP, Shepherd J and Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England Journal of Medicine 2005; 352: 1425-1435.
12. Levy DR and Pearson TA. Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease. Clinical Cardiology 2005; 28: 317-320.
13. Liu D, Jiang J, Zhou H and Hu P. Quantitative determination of atorvastatin and para- hydroxy atorvastatin in human plasma by LC-MS-MS. Journal of Chromatographic Science 2008; 46: 862-866.
14. Ma L, Dong J, Chen XJ and Wang GJ. Development and validation of atorvastatin by LC-ESI-MS and application in bioequivalence research in healthy Chinese volunteers. Chromatographia 2007; 65: 737-741.
15. Macwan JS, Ionita IA, Dostalek M and Akhlaghi F. Development and validation of a sensitive, simple, and rapid method for simultaneous quantitation of atorvastatin and its acid and lactone metabolites by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Analytical and Bioanalytical Chemistry 2011; 400: 423-433.
16. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupein PJ, Jones PH, Haber HE and Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary Hypercholesterolemia by atorvastatin. A new HMG-CoA reductase inhibitor. Arteriosclerosis, Thrombosis and Vascular Biology 1995; 15: 678-682.
17. Nirogi RVS, Kandikere VN, Shukla M, Mudigonda K, Maurya S, Boosi R and Anjaneyulu Y. Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. Biomedical Chromatography 2006; 20: 924-936.
18. Novakova L, Vlckova H, Satinsky D, Sadilek P, Solichova D, Blaha M, Blaha V and Solich P. Ultra high performance liquid chromatography tandem mass spectrometric detection in clinical analysis of simvastatin and atorvastatin. Journal of Chromatography B 2009; 877: 2093-2103.
19. Peoples MC, Halquist MS, Ismaiel O, Mammli MYE, Shalaby A and Karnes HT. Assessment of matrix effects and determination of niacin in human plasma using liquid-liquid extraction and liquid chromatography-tandem mass spectrometry. Biomedical Chromatography 2008; 22: 1272-1278.
20. Pfuhl P, Archer UK, Aring NH, Baumeister A, Tawab MA and Zsilavecz MS. Simultaneous determination of niacin, niacinamide and nicotinuric acid in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2005; 36: 1045-1052.
21. Pieper JA. Understanding niacin formulations. The American Journal of Managed Care 2002; 8: S303-S314.
22. Pilli NR, Mullangi R, Inamadugu JK, Nallapati IK and Rao JVLNS. Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Biomedical Chromatography 2011 (in press). DOI: 10.1002/bmc.1690
23. Sander GE and Giles TD. Hypertension and lipids: lipid factors in the hypertension syndrome. Current Hypertension Reports 2002; 4: 458-463.
24. Tavintharan S and Kashyap ML. The benefits of niacin in atherosclerosis. Current Atherosclerosis Reports 2001; 3: 74-82.
25. US DHHS, FDA and CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine, 2001. Available at: http://www/fda.gov/cder/guidance/index.htm
26. Wang Y, Song M, Hang T, Wen A and Yang L. LC-MS-MS simultaneous determination of niacin, niacinamide and nicotinuric acid in human plasma LC-MS-MS and its application to a human pharmacokinetic study. Chromatographia 2010; 72: 245-253.